Abstract
Objective: Evaluation of multimodal imaging biomarkers in predicting treatment response to intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) Bevacizumab, in aggressive retinopathy of prematurity (A-ROP).
Methods: Non-contact ultra-widefield (NC-UWF) fundus imaging with integrated UWF guided swept source Optical coherence tomography (SS-OCT) was performed prospectively in preterm babies before and after intravitreal anti-VEGF (Bevacizumab) monotherapy.
Results: A-ROP eyes treated with intravitreal anti-VEGF and systemic correction of anemia with blood transfusion (Group1) were analyzed as against only anti-VEGF injected eyes (Group 2). Group 1 eyes showed faster resolution of hemorrhages (p-value 0.030) and faster vascular progression to zone 3 (p-value 0.004). Group 2 A-ROP eyes had higher incidence of reactivation (p-value 0.038), higher incidence of PAR (p-value 0.144) and need for retreatment with laser (p-value 0.001) when compared to Group 1.
